INTRODUCTION
Pregnancy and delivery are considered situations at high risk of bleeding in women with von Willebrand disease (VWD) 1, 2 . While patients with mild deficiency usually show a spontaneous complete correction of basal low FVIII and von Willebrand factor (VWF) during pregnancy, usually patients with dysfunctional (type 2) or severe (type 3) VWD require replacement treatment to avoid immediate or delayed bleeding 3, 4 . Despite the fact that several studies have addressed the risk of bleeding at parturition, very few have evaluated FVIII and VWF changes during pregnancy, the bleeding risk and treatment modality in relationship to the specific VWF gene mutations and response to desmopressin.We have recently reported favourable clinical outcome at delivery using desmopressin in a few women with VWD associated with C1130F mutation 5 and R1205H
(VWD Vicenza) 6 , in whom FVIII and VWF increased poorly during pregnancy. On the contrary, these measurements were fully corrected by the end of pregnancy in a woman with homozygous type 2N VWD R854Q and no specific treatment was required 7 .
We report here FVIII/VWF changes after desmopressin and during pregnancy along with clinical outcome in a series of women with VWD for whom a specific VWF gene mutation and biologic response to a desmopressin test infusion was known.
PATIENTS AND METHODS
Twenty-three women with VWD, previously diagnosed and regularly followed up at the Hemophilia and Thrombosis Center of Vicenza, were included in this study. Six patients (of whom 2 have been previously reported) had R1205H mutation (VWD Vicenza), 6 (of whom 1 has been previously reported) C1130F mutation, 3 C2362F mutation, 2 (1 previously reported) were homozygotes for R854Q, 1 had V1822G and 1 R1374H, 1 was compound heterozygote for a splice site mutation in intron 13 and novel Q77stop mutation
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and 1 for a whole gene deletion and C2671Y missense mutation. Two women had a typical type 2 A VWD mutation (V1665E).
A bleeding questionnaire was administered to each enrolled family member. The full bleeding questionnaire and criteria used to compare the resulting bleeding score are available at http://www.shef.ac.uk/euvwd/bleed_score.htm.
Over a period of 8 years (2000-2007) , these patients have been prospectively followed during pregnancy, with FVIII/VWF measurements assessed and clinical examination performed every three months or as required. The last examination occurred within two to three weeks before delivery. Blood loss at delivery was estimated by the loss occuring during parturition and collected whenever possible with a plastic bag beneath the patient on the the delivery bed.
A test-infusion with desmopressin had been previously carried out in all the patients while non pregnant and the biologic response was evaluated by testing FVIII and VWF measurements at least up to 4 hours post-desmopressin 8 . Informed consent was obtained from each patient prior to the test-infusion with desmopressin.FVIII:C, VWF antigen (VWF:Ag) and VWF ristocetin cofactor activity (VWF:RCo), were assessed as previously described 8 .
RESULTS

Phenotypic results
The baseline characteristics of the 23 patients enrolled in the prospective study are summarized in Table 1 . A variable severity of deficiencies was observed, the lowest FVIII and VWF being present in the women with C1130F and R1205H and in the two compound heterozygotes. Bleeding score was increased in all the patients, apart from those carrying the C2362F mutation.
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Desmopressin test-infusion
The results of the FVIII/VWF levels before and 1, 2, 4 hours after desmopressin are shown in Figure 1 and 2. The increase of VWF and especially of FVIII one hour after infusion in women with R1205H and C1130F was remarkable and their levels remained relatively high also 2 hours later, with a more rapid return to baseline for R1205H. Patients with V1822G and C2362F had somewhat higher basal FVIII:C and VWF levels, which were completely corrected by desmopressin. Patients with R1374H and V1665E mutations had a robust FVIII:C increase and normalized VWF:Ag, but VWF:RCo remained significantly lower, particularly in those with V1665E. While the patient with compound heterozygosity for the splice site mutation in intron 13 and Q77stop mutation had a significant isolated FVIII:C increase, no increase of any of the moieties was evident for the woman with a whole gene deletion and C2671Y missense mutation. The two patients with homozygous R854Q had full FVIII:C normalization.
Influence of pregnancy on FVIII and VWF measurements
FVIII and VWF measurements during pregnancy until delivery are reported in Figure 1 and 2. FVIII:C remained always below 25 IU/dL and VWF below 20 IU/dL even at the end of pregnancy in women with R1205H, while a slightly greater FVIII:C increase was evident in women with C1130F. A full correction of all the moieties was observed for V1822G, C2362F and R854Q. The two patients with compound heterozygosity showed an isolated increase of FVIII:C, while the women with V1665E and R1374H had a normalization of FVIII:C and VWF:Ag but abnormally low VWF:RCo levels persisted ( Figure 2 ).
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Pregnancy and Delivery outcome
The details of previous and present pregnancies outcome are summarized in Table 1 .
Only the woman with R1374H mutation had threatened spontaneous miscarriage with intermittent vaginal bleeding within the first three months with both pregnancies and was None of the woman had signs of water intoxication or serum electrolyte abnormalities prior to discharge.
Nineteen newborns had a mutant VWF allele (10 either R1205H or C1130F, 2 R854Q, 2 Q77stop, 1 C2362F, 1 C2671Y, 1 V1822G, 1 V1665E and 1 R1374H), but no bleeding complication occurred during parturition or neonatal period.
DISCUSSION
Women with VWD are at particular risk of bleeding complications during her lifetime and usually their bleeding severity, as assessed by a standardized bleeding score, is more relevant compared to males with VWD 9 . The large majority of our patients had a significant bleeding score (> 3) and thus the risk of bleeding at parturition might be significant 9 . Only those carrying the C2362F mutation had a normal bleeding score, in keeping with
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previously reported findings 10 .Women with VWD are at increased risk of postpartum hemorrhage if untreated (up to 29% compared with an incidence of 3-5% in the general population) 12 and the risk may persist if anti-hemorrhagic prophylaxis at delivery is not adequate 11 . A recent case-control study of 4,067 deliveries in VWD showed that VWD women have higher risk of primary post-partum hemorrhage (OR 1.5) and fivefold greater risk of being transfused 13 . However, despite this general appreciation of the bleeding risk associated with delivery in VWD, very few data are available on the relationship of FVIII and VWF changes during pregnancy, bleeding risk and treatment modality according to different VWF gene mutations.
In this study, during 2000 -2007 31 consecutive pregnancies occurring in 23 VWD females with known VWF gene defects and with a desmopressin test-infusion available have been prospectively followed-up. As a consequence, the large majority had a severe phenotype, with FVIII:C and/or VWF basal levels < 20 IU/dL (Table I) , at variance with women previously reported in other studies 4 . In mild cases, normalization of FVIII and VWF activities at the end of pregnancy is usually observed and prophylactic treatment is seldom required 1,2 . Remarkably, similar FVIII and VWF changes were observed after desmopressin and during pregnancy in women with R854Q, R1374H, V1665E, V1822G
and C2362F ( Fig. 1 and 2 ), even though factor increase was on the average 20 % greater after DDAVP, and thus the results of a test-infusion could be assumed to predict FVIII and VWF changes during pregnancy in these patients. A discrepant pattern was observed in patients with of C1130F and R1205H mutations. These patients have a shortened VWF survival after desmopressin, but they are able to attain very high levels shortly after infusion 14, 15 . Thus, despite the fact that no significant changes of FVIII/VWF levels were observed during pregnancy, delivery was successfully covered with desmopressin infusions. A 24-hour schedule interval was choosen to minimize the risk of tachyphylaxis and the compound administered soon after delivery to avoid possible risks to the newborn.
Indeed, a single report demonstrated the safety of desmopressin in pregnant women, but only during her first trimester 16 . The importance of desmopressin prophylaxis is underlined by the fact that 13/15 pregnancies in other women with VWD Vicenza, carried out in the past prior to the diagnosis without specific antihemorrhagic prophylaxis, were followed by significant bleeding at parturition and blood transfusion was required in 11/13 (Castaman who has a relative decrease of the largest forms only, benefited from the good VWF:RCo increase observed after desmopressin (Fig. 2) 17 . Delayed bleeding was observed in a woman with V1665E and in the other a previous pregnancy was complicated by bleeding because of suboptimal FVIII/VWF concentrate prophylaxis. Thus, in these women full and prolonged correction of the hemostatic abnormality seems to be required to avoid delayed bleeding.
It is generally held that the correction of FVIII:C in VWD is important for the treatment of soft-tissue and surgical bleeding 20 and that basal levels of FVIII and VWF < 15 U/dL are accompanied by failure to achieve levels > 50 U/dL at the end of pregnancy 21 . In our © F e r r a t a S t o r t i F o u n d a t i o n study, two women with compound heterozygosity and a severe phenotype had a peculiar pattern. These women had an isolated significant increase of FVIII:C alone during pregnancy, who was almost similar to that observed after desmopressin (Figure 2 The identification of mutations among VWD patients is important but can not be considered the sole parameter useful to determine the clinical severity of VWD, a disorder with wide heterogeneity of phenotypes. Indeed, the bleeding score seems to represent in this regard a better tool to appreciate the actual risk of bleeding in specific circumstances 9, 22 .
Neonates affected by type 3 VWD may be at risk of bleeding complications and substitutive treatment required 23 , even though national registries do not report a significant occurrence of bleeding at birth in these patients 24 . However, this risk is even smaller in other types 23 , as confirmed in our newborns who did not have any bleeding complications.
In conclusion, for the first time a large number of women with a known VWF mutation have been characterized for their response to desmopressin and changes during pregnancy. The strict follow-up and detailed guidelines for management of parturition have produced a very low rate of immediate and late bleeding complications. Furthermore, it appears that neonatal risk is very small. The persistence of severely reduced FVIII and VWF levels in women with recessive VWD or C1130F or Vicenza is not accompanied by an increased risk of bleeding during pregnancy or at parturition. Finally, desmopressin is effective and safe in preventing significant bleeding at delivery in most of these patients, even when not all the properties of VWF are fully normalized after desmopressin infusion.
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